Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Argent Biopharma ( (AU:RGT) ) has issued an announcement.
Argent BioPharma announced the issue of 5,000,000 fully paid ordinary shares, taking advantage of an exemption under section 708A(5) of the Corporations Act 2001, which allows the on-sale of securities without disclosure. This move demonstrates the company’s compliance with regulatory requirements and supports its strategic growth, potentially enhancing its market position and providing stakeholders with confidence in its financial and operational transparency.
More about Argent Biopharma
Argent BioPharma Limited is a clinical-stage biopharmaceutical company specializing in neuroimmunology. The company focuses on developing advanced nano-medicines to address unmet medical needs in central nervous system disorders and immune-related conditions. Utilizing cutting-edge technologies like the Neuro-Immune Modulatory System, Argent BioPharma’s pipeline targets complex diseases with lead candidates such as CannEpil®, CogniCann®, and CimetrA®.
YTD Price Performance: 27.50%
Average Trading Volume: 163,509
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.27M
See more insights into RGT stock on TipRanks’ Stock Analysis page.
